Hsinchu, Taiwan

Jing-Po Tsao

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: National Health Research Institutes. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jing-Po Tsao. Retrieved from https://idiyas.com/inventor/jing-po-tsao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 5.8

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Jing-Po Tsao

Introduction

Jing-Po Tsao is a notable inventor based in Hsinchu, Taiwan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target cannabinoid-receptor mediated disorders. With a total of 2 patents to his name, his work is recognized for its potential therapeutic applications.

Latest Patents

One of his latest patents involves selenophene compounds, which are described by a specific formula. These compounds have been identified as having the potential to treat disorders mediated by cannabinoid receptors. Another significant patent pertains to oxadiazole compounds, which also includes a pharmaceutical composition and a method for treating cannabinoid receptor-mediated disorders.

Career Highlights

Jing-Po Tsao is affiliated with the National Health Research Institutes, where he conducts his research and development work. His innovative approach to drug development has positioned him as a key figure in his field.

Collaborations

He has collaborated with notable colleagues, including Jen-Shin Song and Kak-Shan Shia, contributing to a dynamic research environment that fosters innovation.

Conclusion

Jing-Po Tsao's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in treating cannabinoid-receptor mediated disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…